|
Outcome in patients with refractory high-risk neuroblastoma. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Abbvie; Accelerated Medical Diagnostics; Amgen; Amgen (I); Anthem INC; Cardinal Health; Jazz Pharmaceuticals; Lilly; Merck; Novo Nordisk; Pfizer; Pfizer (I); Regeneron; Sanofi; Stryker; Stryker (I); United Therapeutics; United Therapeutics (I); Varex Imaging; Zimmer BioMet |
Research Funding - Merck (Inst); United Therapeutics (Inst) |
|
|
Stock and Other Ownership Interests - Pfizer |
Consulting or Advisory Role - Merck |
Research Funding - Jubilant DraxImage (Inst); Merck (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline |